SLC5A2 and chronic kidney disease: Regarding acute kidney injury or failure of SGLT2 inhibitors in T2DM with CKD, we found that the incidence was slightly lower compared with control group which was also indicated in Cahn trial.[27] In our meta-analysis, there were 2 groups in the EMPA-REG OUTCOME trial[17] and we selected group with eGFR < 59 ml/minutes/1.73 m2.